![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American, Central American and Caribbean countries, which are part of Takeda’s Growth & Emerging Markets Business Unit (GEM BU).
Lead Product(s): Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area: Neurology Product Name: Neosaldina
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hypera Pharma
Deal Size: $825.0 million Upfront Cash: Undisclosed
Deal Type: Divestment January 29, 2021
Details:
The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Business Unit.
Lead Product(s): Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hypera Pharma
Deal Size: $825.0 million Upfront Cash: Undisclosed
Deal Type: Divestment March 02, 2020